Molecule 2 Medicine

molecule2medicine.com

Molecule 2 Medicine Limited (M2M) is a private, UK based, biotechnology and pharmaceutical consulting company assisting global clients with the discovery, development and commercialisation of new human therapeutics. M2M provides clients with the technical skills required to run efficient drug discovery and drug development programs, along with the financial and commercial acumen and “back office” support to help their businesses succeed. M2M ensures that the growth of each client’s science is matched by their corporate development by providing guidance in such areas as venture capital/private equity capital raisings and interactions and negotiations with Pharma partners. M2M assist in creating new biotech businesses, providing operational assistance from the formation stage and guiding the evolution of companies on the right trajectory as they strive to develop new human therapeutics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

news image

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More

CELL AND GENE THERAPY

GRACELL BIOTECHNOLOGIES UNVEILS INNOVATION CENTER IN U.S.

Gracell Biotechnologies Inc | January 13, 2022

news image

Gracell Biotechnologies Inc. a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022. As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and ...

Read More

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

news image

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

news image

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More
news image

CELL AND GENE THERAPY

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More
news image

CELL AND GENE THERAPY

GRACELL BIOTECHNOLOGIES UNVEILS INNOVATION CENTER IN U.S.

Gracell Biotechnologies Inc | January 13, 2022

Gracell Biotechnologies Inc. a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022. As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and ...

Read More
news image

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More
news image

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More